Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
In this podcast episode, we dig further into the practical use of pharmacogenetic testing in psychiatric practice. We address its limitations and the resources you can use to guide your decision making.
In this podcast interview with Dr. Leslie Citrome, we venture into the topic of transdermal delivery of psychotropics. We explore the challenge of creating patches and also peek into the latest antipsychotics in clinical trials for transdermal delivery.
In this podcast episode, we revisit psychedelics with Dr. David Nutt and Dr. Robin Carhart-Harris. We review how psychedelics work, their potential uses, and adverse effects in managing treatment-resistant depression. We also discuss the use of MDMA in PTSD.
In this podcast episode, we explore with Dr. David Nutt (Imperial College London) the serotonin receptors 5-HT1A and 5-HT2A and their links to clinical psychiatry. We particularly focus on their roles in mood, anxiety, psychosis, aggression, and learning.
In this podcast episode, we answer the question: What if you can’t use an SSRI for GAD? With expert commentary from Dr. David Osser (Harvard Medical School), we explore different options and also highlight what not to use.
In this podcast episode, we learn about prescribing natural medications in psychiatry with Dr. David Mischoulon (Harvard Medical School). We explore St. John’s wort, SAM-e, Omega 3 fatty acids and Rhodiola rosea.
In this episode, we cover practical tips on the management of fever, cardiovascular and cardiometabolic adverse effects related to clozapine use. Dr. Jonathan Meyer provides evidence-based pearls as well as clinical anecdotes.
In this episode, we cover practical tips on the management of sialorrhea, constipation, sedation, and seizures related to clozapine use. Dr. Jonathan Meyer provides evidence-based pearls as well as clinical anecdotes.
In this episode we answer the question: Do SSRIs increase the risk of bleeding? We do this with Dr. James Levenson (Virginia Commonwealth University) and we explore GIT, perioperative, CNS and postpartum bleeding with SSRIs.
In this episode, we explore the management of common PTSD comorbidities with Prof. David Osser (Harvard Medical School). We cover substance use disorder, depression, psychosis and prescribing in women of childbearing potential.
In this episode, we discuss part of Dr. David Osser’s (Harvard Medical School) PTSD algorithm about treating sleep symptoms of PTSD. We cover the evidence on prazosin’s efficacy and trazodone use. The rationale behind certain drugs to avoid is also covered.
In this episode, we learn to prescribe with the gut in mind. Dr. James Levenson (Virginia Commonwealth University) joins us with to-the-point tips on prescribing psychotropics in patients with GI disease as well as exploring how psychotropics can affect the GIT.
In this episode, we uncover clinical pearls of geriatric psychopharmacology. We are joined by Dr. Sandra Jacobson of the University of Arizona giving practical tips on prescribing for this special group of patients.
In this podcast episode, we take on the challenge of treatment-resistant depression and its therapeutic options. Dr. Philip Cowen (University of Oxford) provided insights for this clinical conundrum with a simple algorithm.
In this episode, we venture into the psychopharmacology of agitation, with a special focus on psychotic agitation. Dr. Michael Jibson (University of Michigan) and Dr. David Osser (Harvard Medical School) shared clinical pearls to treat this challenging situation.
Dr. Jeffrey Mattes, psychiatrist in Princeton, New Jersey speaks about drug interaction warnings that appear during electronic prescribing and how these warnings may be influenced by drug company promotion.
This interview is part of a series covering the 2018 ASCP Annual Meeting.
Dr. Robin Carhart-Harris speaks about the use of psilocybin for treatment-resistant depression.
- Psilocybin, a psychedelic, is a 5-HT2A agonist. Stimulation of the 5-HT2A receptor promotes neural plasticity
-A potential mechanism of action of psilocybin in treatment-resistant depression involves “brain resetting”
- Psilocybin has a good safety profile. However, patients may experience challenging psychological experiences that may turn out to be frightening for some people
At the 2018 Annual Meeting of the American Psychiatric Association, Dr. Robert Patterson (psychiatrist at McLean Hospital Boston) spoke about the benefits of following a structured approach to psychopharmacology.
In this episoder, Dr. Patterson explains why algorithms are good for patient outcomes and how they support clear decision making.